Omalizumab received initial approval from the U.S. Food and Drug Administration (FDA) in 2003 for the treatment of moderate-to-severe asthma. Subsequently, in 2014, the drug was also approved for use in patients with chronic idiopathic or spontaneous urticaria in the United States and Europe. Omalizumab is a recombinant humanized immunoglobulin G1 (IgG1) monoclonal anti-IgE antibody utilized to treat allergic asthma and chronic urticaria. This medication works by interacting with the high-affinity receptor Fc-epsilon-RI, typically found on eosinophils, mast cells, and basophils, therefore playing a critical role in preventing the allergic cascade. As a result, omalizumab plays a vital role in managing moderate-to-severe IgE-mediated asthma and, more recently, in treating chronic urticaria. This activity will comprehensively cover the indications, contraindications, mechanisms of action, pharmacokinetics, adverse effects, warnings, precautions, and monitoring requirements of omalizumab. In addition, this activity will also provide updates on some of the critical studies implemented primarily for asthma and include information on urticarial reactions.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/26162
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABA - 1.0 Point; Credit Type(s): Lifelong Learning (ABA)
ABTS - 1.0 Point; Credit Type(s): Accredited CME (ABTS)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS)
ABP - 1.0 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP)
ABOHNS - 1.0 Point; Credit Type(s): Self-Assessment (ABOHNS)
ABTS - 1.0 Point; Credit Type(s): Self-Assessment (ABTS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Adolescent Medicine, Allergy, Ambulatory/Outpatient, Cardiothoracic, Chemical Pathology, Gastroenterology, General Operative Anesthesia, General Otolaryngology, General Pediatrics, General Surgery, Hospital Medicine, Infectious Disease, Internal Medicine, Medical Toxicology, Pediatric Emergency Medicine, Pediatric Pulmonology, Pulmonary Disease